GEN - Genetic Engineering and Biotechnology News2d
From Tools to Trials: Editing Therapy Companies Pivot to Development
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
The Manila Times1d
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure ...
Investing4d
Earnings call transcript: Inovio Q4 2024 sees narrowed losses, strategic focus
Inovio’s performance in Q4 2024 shows a strategic shift towards reducing costs and focusing on core projects. The company’s operating expenses were trimmed by 22%, down from $144.8 million in ...
Investing3d
Earnings call transcript: Inovio Q4 2024 sees narrowed losses, strategic focus
Inovio is advancing its DNA-encoded monoclonal antibody technology. Inovio’s performance in Q4 2024 shows a strategic shift towards reducing costs and focusing on core projects. The company’s ...
University of Sheffield2d
Professor Thushan de Silva
I am an Infectious Diseases Clinician Scientist with a programme of research centred around clinical discovery science in the UK and Africa. Our group applies a broad range of methods including human ...
gut.bmj2d
Serum macrophage inflammatory protein 3α levels predict the severity of HBV-related acute-on-chronic liver failure
We collected serum samples from 420 patients with HBV-ACLF, 121 patients with chronic hepatitis B (CHB) and 25 normal controls to identify novel serological biomarkers of HBV-ACLF (see online ...